Edition:
United Kingdom

3SBio Inc (1530.HK)

1530.HK on Hong Kong Stock

14.92HKD
3:22am BST
Change (% chg)

HK$0.28 (+1.91%)
Prev Close
HK$14.64
Open
HK$14.38
Day's High
HK$15.22
Day's Low
HK$14.02
Volume
4,516,500
Avg. Vol
13,287,146
52-wk High
HK$23.25
52-wk Low
HK$9.63

Latest Key Developments (Source: Significant Developments)

3SBio Inc Posts FY Net Profit Attributable RMB935.4 Mln
Monday, 26 Mar 2018 

March 26 (Reuters) - 3Sbio Inc <1530.HK>::FY NET PROFIT ATTRIBUTABLE RMB935.4 MILLION VERSUS RMB712.6 MILLION.RECOMMENDED PAYMENT OF FINAL DIVIDEND OF HKD6.85 CENTS PER ORDINARY SHARE.FY REVENUE UP 33.5% TO RMB3,734.3 MILLION.  Full Article

3Sbio Says Unit And Toray Sign Exclusive Licensing Agreement On Antipuritic Agent, TRK-820​
Monday, 15 Jan 2018 

Jan 15 (Reuters) - 3Sbio Inc <1530.HK>::UNIT AND TORAY ENTER EXCLUSIVE LICENSING AGREEMENT ON CERTAIN ORAL DISINTEGRATION TABLET FORMULATION OF ANTIPRURITIC DRUG TRK-820​.  Full Article

3SBio Says ‍China FDA Approves New Once-Weekly Bydureon To Improve Glycemic Control​
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - 3Sbio Inc <1530.HK>::‍CHINA FDA APPROVES NEW ONCE-WEEKLY BYDUREON TO IMPROVE GLYCEMIC CONTROL​.  Full Article

3SBio Inc says 601a approved by China FDA for clinical trials ​
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - 3SBio Inc <1530.HK>:Recombinant humanized anti-VEGF monoclonal antibody for injection (601a) approved by China FDA for clinical trials ​.  Full Article

UPDATE 3-China's Ascletis closes flat on debut in HK's first float under new biotech rules

* At least 10 more biotechs plan HK listings this year (Recasts; adds Ascletis' stock close)